Research programme: viral infections therapeutics - Aqualis

Drug Profile

Research programme: viral infections therapeutics - Aqualis

Alternative Names: CP-4018; ganciclovir elaidate - Aqualis; ganciclovir elaidic acid - Aqualis

Latest Information Update: 17 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis
  • Class Hypoxanthines; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Herpes simplex virus infections; Viral infections

Highest Development Phases

  • Discontinued Herpes simplex virus infections; Viral infections

Most Recent Events

  • 29 Aug 2013 Discontinued - Preclinical for Herpes simplex virus infections in Norway (unspecified route)
  • 29 Aug 2013 Discontinued - Preclinical for Viral infections in Norway (unspecified route)
  • 07 Feb 2011 Research programme: viral infections therapy - Clavis is available for licensing as of 07 Feb 2011. http://www.clavispharma.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top